Litigation Or Legislation: States Have Dual Path For Pharma Regulation
States make decisions about whether to use legislation or litigation to address questionable behavior by pharmaceutical companies based on the required scope and speed of the remedial activity, Vermont Assistant Attorney General Julie Brill said
You may also be interested in...
Pharmaceutical companies should beware of pitfalls of communicating about off-label uses even when such activities can be defended as free speech, Philadelphia Associate U.S. Attorney Jim Sheehan suggested
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications